vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Primerica, Inc. (PRI). Click either name above to swap in a different company.
Primerica, Inc. is the larger business by last-quarter revenue ($853.7M vs $598.7M, roughly 1.4× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 23.1%, a 17.8% gap on every dollar of revenue. On growth, Primerica, Inc. posted the faster year-over-year revenue change (11.0% vs 5.6%). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 7.2%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Primerica, Inc. is a multi-level marketing company that provides insurance, investment and financial services to middle-income families in the United States and Canada.
EXEL vs PRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $853.7M |
| Net Profit | $244.5M | $197.0M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | 28.9% |
| Net Margin | 40.8% | 23.1% |
| Revenue YoY | 5.6% | 11.0% |
| Net Profit YoY | 74.8% | 17.9% |
| EPS (diluted) | $0.89 | $6.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $853.7M | ||
| Q3 25 | $568.3M | $839.9M | ||
| Q2 25 | $555.4M | $793.3M | ||
| Q1 25 | $566.8M | $804.8M | ||
| Q4 24 | — | $768.8M | ||
| Q3 24 | $539.5M | $774.1M | ||
| Q2 24 | $637.2M | $803.4M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $197.0M | ||
| Q3 25 | $184.8M | $206.8M | ||
| Q2 25 | $159.6M | $178.3M | ||
| Q1 25 | $139.9M | $169.1M | ||
| Q4 24 | — | $167.1M | ||
| Q3 24 | $118.0M | $164.4M | ||
| Q2 24 | $226.1M | $1.2M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | 98.0% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 28.9% | ||
| Q3 25 | 37.6% | 32.3% | ||
| Q2 25 | 33.6% | 29.6% | ||
| Q1 25 | 28.8% | 27.5% | ||
| Q4 24 | — | 64.7% | ||
| Q3 24 | 25.2% | 32.9% | ||
| Q2 24 | 43.3% | 1.0% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 23.1% | ||
| Q3 25 | 32.5% | 24.6% | ||
| Q2 25 | 28.7% | 22.5% | ||
| Q1 25 | 24.7% | 21.0% | ||
| Q4 24 | — | 21.7% | ||
| Q3 24 | 21.9% | 21.2% | ||
| Q2 24 | 35.5% | 0.1% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $6.11 | ||
| Q3 25 | $0.65 | $6.35 | ||
| Q2 25 | $0.55 | $5.40 | ||
| Q1 25 | $0.47 | $5.05 | ||
| Q4 24 | — | $4.92 | ||
| Q3 24 | $0.40 | $4.83 | ||
| Q2 24 | $0.77 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $756.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $2.4B |
| Total Assets | $2.8B | $15.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $756.2M | ||
| Q3 25 | $791.1M | $644.9M | ||
| Q2 25 | $1.0B | $621.2M | ||
| Q1 25 | $1.1B | $625.1M | ||
| Q4 24 | — | $687.8M | ||
| Q3 24 | $1.2B | $550.1M | ||
| Q2 24 | $1.0B | $627.3M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $2.4B | ||
| Q3 25 | $2.0B | $2.3B | ||
| Q2 25 | $2.1B | $2.3B | ||
| Q1 25 | $2.2B | $2.3B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | $2.3B | $1.9B | ||
| Q2 24 | $2.1B | $2.1B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $15.0B | ||
| Q3 25 | $2.7B | $14.8B | ||
| Q2 25 | $2.8B | $14.8B | ||
| Q1 25 | $2.9B | $14.6B | ||
| Q4 24 | — | $14.6B | ||
| Q3 24 | $3.0B | $14.8B | ||
| Q2 24 | $2.8B | $14.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $338.2M |
| Free Cash FlowOCF − Capex | $332.4M | — |
| FCF MarginFCF / Revenue | 55.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 1.36× | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $338.2M | ||
| Q3 25 | $49.0M | $202.9M | ||
| Q2 25 | $211.4M | $162.6M | ||
| Q1 25 | $240.3M | $197.5M | ||
| Q4 24 | — | $270.6M | ||
| Q3 24 | $271.3M | $207.3M | ||
| Q2 24 | $119.5M | $173.3M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | — | ||
| Q3 25 | $46.2M | — | ||
| Q2 25 | $208.5M | — | ||
| Q1 25 | $236.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $263.1M | — | ||
| Q2 24 | $113.0M | — |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | — | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 37.5% | — | ||
| Q1 25 | 41.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 48.8% | — | ||
| Q2 24 | 17.7% | — |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 1.0% | — |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 1.72× | ||
| Q3 25 | 0.27× | 0.98× | ||
| Q2 25 | 1.32× | 0.91× | ||
| Q1 25 | 1.72× | 1.17× | ||
| Q4 24 | — | 1.62× | ||
| Q3 24 | 2.30× | 1.26× | ||
| Q2 24 | 0.53× | 147.98× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
PRI
| Revenues From Sources Other Than Contracts With Customers | $445.9M | 52% |
| Investment And Savings Products Segment Revenues | $340.3M | 40% |
| Other | $56.5M | 7% |
| Segment Revenues From Contracts With Customers | $11.0M | 1% |
